At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 676 enrolled
Drug / intervention
Prospekta +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-blind, Placebo-controlled, Parallel-group, Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Patients With Post-COVID-19 Asthenia.
In Brief
A Phase 3 clinical trial evaluating Prospekta and Placebo for Post-acute COVID-19 Syndrome. Completed, enrolled 676 participants across 32 sites.
Detailed Summary
The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Prospekta in the treatment of asthenia in patients after the coronavirus infectious disease (COVID-19).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-acute COVID-19 Syndrome
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartOct 2021
Primary CompletionJun 2022
TodayJul 2026
First PostedOct 12, 2021
Enrollment StartOct 15, 2021
Primary CompletionJun 8, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.7 years ago
Interventions
Prospektadrug
Oral administration.
Placebodrug
Oral administration.